Abstract
Ovarian carcinoma (OC) is one of the most lethal gynecological malignancies. Galectin-8 (Gal-8) and the VEGF-C/VEGFR-3 lymphangiogenic axis have each been implicated in OC progression, but they have not been examined together in a histotype-resolved series. In this retrospective, cross-sectional, single-center study of 84 epithelial OC cases, Gal-8, VEGF-C and VEGFR-3 immunoexpression was related to histological type, Type I/Type II classification, pT-based stage and residual disease, with correction for multiple testing (q). Gal-8 was nuclear in all 34 high-grade serous carcinomas (HGSCs) and all 42 Type II tumors, whereas cytoplasmic and mixed patterns occurred almost only in low-grade and Type I tumors. A high Gal-8 score was associated with HGSC and Type II histology, poor differentiation, advanced stage and residual disease (odds ratios, all q ≤ 0.004). VEGF-C and VEGFR-3 were expressed in 67.86% and 73.81% of cases, more often in high-grade and advanced tumors, and in all stage III tumors. No statistically significant association was detected between Gal-8 and VEGF-C or VEGFR-3, but the cohort was too small for this comparison to be conclusive. Gal-8, VEGF-C and VEGFR-3 are each associated with aggressive features of OC. This study cannot show whether this reflects a shared aggressive phenotype or a functional interaction between the markers. Without outcome data or multivariable analysis, these findings are descriptive, not prognostic, and hypothesis-generating.